MEDVi is a good fit if you value hands-on clinical oversight and don't mind the price jump after month one
Were not coming for Lemon Bottle and we also wont judge you if you choose to offer it in your clinic, this is just our opinion and for us based on the research we have gathered, its a firm no
However, it can be a difficult conversation to have with the patient when insurance does not cover chronic management for these medications, causing them to have to pay out of pocket
SOURCE: #Obesity #Obesityinsights #tirzepatide #liraglutide #orforglipron #servodutide #bimagrumab #retatrutide #cardiokidneymetabolic #mash #masld #steatohepatitis #adiposity #Semaglutide #Wegovy #GLP1 #WomenHealth #Menopause #CardiometabolicHealth #MedicalEducation To view or add a comment, sign in Everyone knows GLP-1 agonists for Type 2 Diabetes and Obesity
Lilly reportedly plans to seek FDA approval for this use and if approved, the drug would be the first pharmaceutical treatment on the market for sleep apnea
Office of the Commissioner